A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction

References

• van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;(3):CD002095.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104:252–258.
   PubMed Web of Science ®Google Scholar
• Ness-Jensen E, Lindam A, Lagergren J, et al. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012;61:1390–1397.
   PubMed Web of Science ®Google Scholar
• Haag S, Andrews JM, Katelaris PH, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80:226–234.
   PubMed Web of Science ®Google Scholar
• Earnest D, Robinson M, Rodriguez-Stanley S, et al. Managing heartburn at the ‘base’ of the GERD ‘iceberg’: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000;14:911–918.
   PubMed Web of Science ®Google Scholar
• Nexium 24HR [product labeling]. Madison (NJ): Pfizer Consumer Healthcare; 2014.
   Google Scholar
• Nexium control (esomeprazole) [summary of product characteristics]. Kent (UK): Pfizer Consumer Healthcare Ltd.; 2014.
   Google Scholar
• Peura DA, Traxler B, Kocun C, et al. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014;126:33–41.
   PubMed Web of Science ®Google Scholar
• Peura DA, Riff DS, Snoddy AM, et al. Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther. 2009;30:459–468.
   PubMed Web of Science ®Google Scholar
• Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–87, 7.
   PubMed Web of Science ®Google Scholar
• Lodrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515–522.
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46.
   PubMed Web of Science ®Google Scholar
• Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16:445–454.
   PubMed Web of Science ®Google Scholar
• Kushner PR, Snoddy AM, Gilderman L, et al. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121:67–75.
   PubMed Web of Science ®Google Scholar
• Tack J, Becher A, Mulligan C, et al. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35:1257–1266.
   PubMed Web of Science ®Google Scholar
• Hacker F, Morck H. Self-medication of upper gastrointestinal symptoms with hydrotalcite: a noninterventional community pharmacy study on drug usage and patient satisfaction. Int J Clin Pharmacol Ther. 2012;50:87–99.
   PubMed Web of Science ®Google Scholar
• Nocon M, Labenz J, Jaspersen D, et al. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study. Aliment Pharmacol Ther. 2009;29:662–668.
   PubMed Web of Science ®Google Scholar
• Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415–3422.
   PubMed Web of Science ®Google Scholar
• Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease– an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–154.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Qvigstad G, Fossmark R, et al. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45:389–394.
   PubMed Web of Science ®Google Scholar
• Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology. 2004;126:980–988.
   PubMed Web of Science ®Google Scholar
• Metz DC, Pilmer BL, Han C, et al. Lack of acid and symptom rebound after withdrawal of 4 to 8 weeks of dexlansoprazole MR or lansoprazole therapy [abstract W1104]. Gastroenterology. 2010;138:S–652.
   Web of Science ®Google Scholar
• Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol. 2011;46:398–405.
   PubMed Web of Science ®Google Scholar
• Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.
   PubMed Web of Science ®Google Scholar
• Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105:1531–1537. Epub 2010 Mar 25.
   PubMed Web of Science ®Google Scholar